The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday authorized GSK plc’s (NYSE:GSK) Blenrep. Blenrep is approved for the treatment of adults with multiple myeloma in ...

If a new package of pivotal data satisfies the FDA, GSK could have another run at the U.S. multiple myeloma market with its previously withdrawn BMCA-targeted antibody-drug conjugate, Blenrep. GSK ...

The European Medicines Agency (EMA) has accepted for review GSK’s marketing authorisation application (MAA) for Blenrep (belantamab mafodotin), an antibody-drug conjugate (ADC), to treat relapsed or ...

GSK on Monday said its drug Blenrep outperformed Johnson & Johnson’s Darzalex in a clinical trial of people with the blood cancer multiple myeloma, potentially cracking open the door to Blenrep’s ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks to a key patient survival win. The antibody-drug conjugate (ADC) has ...

FDA advisors have voted that the benefit/risk profile of GSK's multiple myeloma therapy, Blenrep, does not support its approval in the US – denting the prospects of one of the company's top growth ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an increase in overall survival (OS) with the drug had reached statistical ...

The FDA accepted a BLA for Blenrep combinations for multiple myeloma treatment after prior therapy. DREAMM-7 and DREAMM-8 trials showed significant improvements in progression-free survival and ...

Significant unmet need for patients requires new and novel treatments1 DREAMM-7 showed a 51% reduction in the risk of death and tripled median progression-free survival in 3L+ indicated population ...

The Blenrep comeback continues for GSK. The blood cancer treatment, which was once pulled off the market, was found to help patients live longer in a Phase 3 clinical trial, the results of which were ...

CURE spoke with Dr. Surbhi Sidana about the recently approved antibody-drug conjugate Blenrep for multiple myeloma. On Oct. 23, it was announced that the U.S. Food and Drug Administration (FDA) ...

GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for the ...